The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses
Abstract BRAF mutations are the oncogenic drivers in colorectal cancer and V600 mutations (Class1), which lead to RAS-independent active monomers, are the most common mutation types. BRAF non-V600 mutants can be further classified as RAS-independent active dimers (Class2) and RAS-dependent impaired...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Book |
| Published: |
BMC,
2023-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_b5c38b1247d04bf8a6ea1dba18368eb0 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Yungchang Chen |e author |
| 700 | 1 | 0 | |a Hao Sun |e author |
| 700 | 1 | 0 | |a Yanhong Deng |e author |
| 700 | 1 | 0 | |a Yutong Ma |e author |
| 700 | 1 | 0 | |a He Huang |e author |
| 700 | 1 | 0 | |a Yang Liu |e author |
| 700 | 1 | 0 | |a Yaru Zhang |e author |
| 700 | 1 | 0 | |a Hongyu Zhang |e author |
| 700 | 1 | 0 | |a Sheng Ye |e author |
| 700 | 1 | 0 | |a Mingyan E |e author |
| 700 | 1 | 0 | |a Hongqiang Guo |e author |
| 700 | 1 | 0 | |a Mengmeng Wu |e author |
| 700 | 1 | 0 | |a Chunman Wu |e author |
| 700 | 1 | 0 | |a Xingxiang Pu |e author |
| 700 | 1 | 0 | |a Xinggui Chen |e author |
| 700 | 1 | 0 | |a Chaoyong Liang |e author |
| 700 | 1 | 0 | |a Qiuxiang Ou |e author |
| 700 | 1 | 0 | |a Huawei Weng |e author |
| 700 | 1 | 0 | |a Xue Wu |e author |
| 700 | 1 | 0 | |a Yang Shao |e author |
| 700 | 1 | 0 | |a Anxin Gu |e author |
| 700 | 1 | 0 | |a Tongyu Lin |e author |
| 245 | 0 | 0 | |a The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses |
| 260 | |b BMC, |c 2023-01-01T00:00:00Z. | ||
| 500 | |a 10.1186/s40364-022-00443-8 | ||
| 500 | |a 2050-7771 | ||
| 520 | |a Abstract BRAF mutations are the oncogenic drivers in colorectal cancer and V600 mutations (Class1), which lead to RAS-independent active monomers, are the most common mutation types. BRAF non-V600 mutants can be further classified as RAS-independent active dimers (Class2) and RAS-dependent impaired kinase (Class3). We retrospectively reviewed the mutational profiles of 328 treatment-naïve colorectal tumors with BRAF mutations detected using capture-based hybrid next-generation sequencing targeting 400 + cancer-related genes. The clinical and genetic distinctions of patients harboring Class1/2/3 BRAF mutations were investigated, which revealed that tumors with Class1 BRAF mutations showed more unique genomic profiles than those with Class2/3 mutations. Also, by using an external dataset from cBioPortal, we demonstrated that patients with Class3 BRAF mutations had the best survival outcomes compared to the other two subgroups. These findings promoted the development of anti-BRAF strategies by distinguishing BRAF mutant subgroups. | ||
| 546 | |a EN | ||
| 690 | |a BRAF | ||
| 690 | |a Colorectal cancer | ||
| 690 | |a Next-generation sequencing | ||
| 690 | |a Prognosis | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Biomarker Research, Vol 11, Iss 1, Pp 1-6 (2023) | |
| 787 | 0 | |n https://doi.org/10.1186/s40364-022-00443-8 | |
| 787 | 0 | |n https://doaj.org/toc/2050-7771 | |
| 856 | 4 | 1 | |u https://doaj.org/article/b5c38b1247d04bf8a6ea1dba18368eb0 |z Connect to this object online. |